Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Prostate cancer immunotherapy.

Douglas G McNeel1

  • 1Department of Medicine, University of Wisconsin Comprehensive Cancer Center, Madison, Wisconsin 53792, USA. dm3@medicine.wisc.edu

Current Opinion in Urology
|April 7, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Activation of tumor-specific CD8+ T cells prior to radiopharmaceutical therapy improves antitumor response.

Journal for immunotherapy of cancer·2026
Same author

Overall Survival of Patients With PSA-Recurrent Prostate Cancer: Long-Term Analysis of a Randomized Phase 2 Trial of pTVG-HP DNA Vaccine Versus Placebo.

Clinical genitourinary cancer·2026
Same author

Plasmid DNA vaccines encapsulated in lipid nanoparticles elicit STING-dependent type 1 interferon release.

Molecular therapy. Advances·2026
Same author

Phase 2 trial of pTVG-HP ± pTVG-AR DNA vaccines and pembrolizumab in patients with metastatic, castration-resistant prostate cancer (mCRPC).

Journal for immunotherapy of cancer·2026
Same author

Androgen deprivation, androgen receptor-targeted vaccination, and nivolumab in patients with high-risk localized prostate cancer.

Journal for immunotherapy of cancer·2026
Same author

Toll like receptor agonist effects on human CD8+ T cell activation and expression of T cell checkpoint receptors.

Human vaccines & immunotherapeutics·2025
Same journal

Pediatric andrology: bridging pediatric urology and reproductive medicine.

Current opinion in urology·2026
Same journal

Current impact of simulation-based surgical training in urology: a review from the European School of Urology and the European Association of Urology Endourology Section.

Current opinion in urology·2026
Same journal

Personalized therapy in metastatic hormone-sensitive prostate cancer: a 2026 update on navigating therapeutic complexity.

Current opinion in urology·2026
Same journal

Role and relevance of genetic testing in patients with kidney stones: a review from EAU Section of Endourology.

Current opinion in urology·2026
Same journal

Advances in evaluating and delivering nontechnical skills training: The use of simulation, robotics, artificial intelligence and virtual reality.

Current opinion in urology·2026
Same journal

Educating for a sustainable future: faculty and student perspectives and a review of environmental sustainability in medical education - an EAU endourology study.

Current opinion in urology·2026
See all related articles

Recent advances in cancer immunology have led to promising immunotherapies for prostate cancer. Clinical trials show these treatments are effective and may have fewer side effects than traditional therapies.

Area of Science:

  • Immunology
  • Oncology
  • Urology

Background:

  • Decades of basic immunology research have elucidated tumor recognition and immune evasion mechanisms.
  • This foundational knowledge has paved the way for novel cancer immunotherapies.

Purpose of the Study:

  • To review recent findings in prostate cancer immunotherapies.
  • Focus on passive and active immunotherapy approaches in clinical trials.

Main Methods:

  • Review of published literature on prostate cancer immunotherapies.
  • Analysis of clinical trial data for active and passive immunotherapies.

Main Results:

  • Recent clinical trials demonstrate efficacy of immune-active agents in prostate cancer.

Related Experiment Videos

  • Examples include granulocyte-macrophage colony stimulating factor, CTLA-4 antibodies, PSMA-targeting antibodies, and various vaccines.
  • These therapies show potential for clinical benefit with reduced toxicity.

    • Conclusions:

    • Immune-based therapies show clinical benefit in prostate cancer patients.
    • These treatments offer a potentially less toxic alternative to traditional systemic therapies.
    • Future directions include combination therapies with other immunotherapies and conventional treatments.